

Shyam M Kavuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3986121/publications.pdf>

Version: 2024-02-01

11
papers

1,228
citations

1040056

9
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

3055
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-24-P2-13-24.	0.9	0
2	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. <i>Nature Communications</i> , 2021, 12, 2940.	12.8	14
3	Thioredoxin reductase is a major regulator of metabolism in leukemia cells. <i>Oncogene</i> , 2021, 40, 5236-5246.	5.9	11
4	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. <i>Oncogene</i> , 2020, 39, 6265-6285.	5.9	52
5	The prognostic effects of somatic mutations in ER-positive breast cancer. <i>Nature Communications</i> , 2018, 9, 3476.	12.8	89
6	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , 2018, 24, 1434-1444.e7.	6.4	73
7	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , 2017, 8, 14864.	12.8	112
8	Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 588-597.	1.5	46
9	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 1168-1183.	9.4	58
10	HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1061-1064.	4.9	70
11	Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. <i>Cancer Discovery</i> , 2013, 3, 224-237.	9.4	697